Physician profile
Racheal Mitchell
NPI 1689021834
$954.30
in general payments reported to CMS, 2019-2025
17 companies · $611 in 2025
The $611 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.05 · 2022: $88.85 · 2023: $122 · 2024: $120 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $379.23 | 2025 | Epclusa, Biktarvy |
| Theratechnologies INC. | $166.01 | 2022-2025 | Trogarzo, Egrifta |
| Cequr Corporation | $121.88 | 2025 | Cequr Simplicity |
| Exact Sciences Corporation | $47.36 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.04 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $33.39 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $24.04 | 2025 | |
| Abiomed | $20.03 | 2024 | Impella |
| Viiv Healthcare Company | $16.85 | 2025 | Rukobia |
| Merck Sharp & Dohme LLC | $14.75 | 2025 | Gardasil 9, Capvaxive |
| Neurocrine Biosciences, INC. | $14.70 | 2023 | Ingrezza |
| Pfizer INC. | $14.63 | 2025 | |
| Edwards Lifesciences Corporation | $14.42 | 2024 | Sapien 3 Ultra Resilia |
| Sanofi Pasteur INC. | $14.26 | 2022 | |
| Shield Therapeutics INC | $12.73 | 2023 | Accrufer |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12.05 | 2021 | |
| Medtronic, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Racheal Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.